144 ·Filed Jun 3, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001950047-26-005565
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a de minimis proposed sale by a director. No actionable signal for traders — the filing is routine and carries no material information about company fundamentals or insider sentiment. Monitor for any larger insider sales ahead of next earnings.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
XERS ▲ +37.89% at T+60d
NEUTRAL call ✓ call won +37.89% · α vs SPY +36.01% · entry $6.15 → $8.48
Entry anchored
Jun 3, 03:59 PM ET
via exchange tick
T+1d
+0.49%
call +0.49% · α +3.06%
$6.18
settled 4mo ago
T+5d
+12.68%
call +12.68% · α +15.24%
$6.93
settled 4mo ago
T+20d
+34.63%
call +34.63% · α +36.01%
$8.28
settled 3mo ago
T+60d
+37.89%
call +37.89% · α +36.01%
$8.48
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Director Marla Persky filed a Form 144 notice of intent to sell 15,500 shares of XERS common stock, with an estimated aggregate market value of $93,000. The shares were acquired via restricted stock units on June 3, 2026. This is a small, routine sale by a non-executive director — the dollar value is negligible relative to the company's $1.1B market cap and represents no material insider signal.

Key Facts

  • Filer: Director Marla Persky (non-executive board member)
  • Shares to be sold: 15,500 shares of common stock
  • Estimated value: $93,000 (based on filing date price of ~$6.00/share)
  • Shares acquired via restricted stock units on June 3, 2026
  • Sale intended to be executed through Morgan Stanley Smith Barney
  • Market cap of XERS: ~$1.1B — sale represents ~0.008% of market cap
  • Recent insider activity (30d): 1 prior sell totaling $101K

Financial Impact

Proposed sale of $93,000 in stock by a director — immaterial relative to $1.1B market cap

dilution

Risk Factors

  • No material risk identified from this filing alone

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005565
Document: 0001950047-26-005565-index.html0001950047-26-005565
Document: 0001950047-26-005565.txt0001950047-26-005565
14 reports for XERS
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+60▲ +24.89%Jun 12, 2026
Filters
Rows
Reports for XERS — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
8-K
BULLISH ★ 6/10
$7.71 $7.78▲ +0.91%▲ +1.56%$9.08 (+17.77%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$8.58 $7.67▼ −10.61%▼ −9.65%$9.08 (+5.83%)
Aug 6, 2026
8w ago
8-K
BULLISH ★ 7/10
$7.36 $8.33▲ +13.18%▲ +11.97%$9.08 (+23.37%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.19 $8.39▲ +2.44%▲ +2.54%$9.08 (+10.87%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 4/10
$8.94 $8.28▲ +7.38%▲ +7.93%$9.08 (−1.57%)
Jul 2, 2026
13w ago
3
NEUTRAL ★ 3/10
$8.28 $8.62▲ +4.11%▲ +3.18%$9.08 (+9.66%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 4/10
$8.28 $8.62▲ +4.11%▲ +3.18%$9.08 (+9.66%)
Jun 30, 2026
13w ago
8-K
NEUTRAL ★ 2/10
$8.00 $8.94▲ +11.75%▲ +11.49%$9.08 (+13.50%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 4/10
$6.79 $6.95▲ +2.36%▲ +1.68%$9.08 (+33.73%)
Jun 5, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.24 $6.88▲ +10.26%▲ +8.14%$9.08 (+45.51%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (38h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access